Abstract
Aims and Objective: In this study, an attempt was made to synthesize, characterize, and develop many applications of functionalized rare metal oxide nanoparticles. Herein, a new strategy for drug delivery is developed to functionalize magnetite nanoparticles to improve their performances in the delivery of celecoxib.
Materials and Methods: Magnetite Fe3O4@SiO2 nanoparticles are synthesized by the sol-gel method. The surface of the hydroxyl groups was extended by treating with cerium nitrate salt; finally, sodium hydroxide was anchored to the surface hydroxyl groups to produce cerium oxidefunctionalized Fe3O4@SiO2@CeO2 magnetic nanoparticles (FSC). The synthesized sample was characterized by FT-IR, FESEM, VSM, TGA, and XRD. Afterward, the functionalized nanoparticles were examined in the delivery of celecoxib as an active drug model involving cerium oxide and hydroxyl functional groups.
Results: For this purpose, the amount of loading/release of the drug was investigated in different amounts of nanocomposite and pH values.
Conclusion: The results of the present investigation indicate that the formulations (mFSC=5 mg, pH=3.3) can be considered as best among various formulations with respect to particle size, entrapment efficiency, and in-vitro successful drug release.
Keywords: Celecoxib, drug delivery, magnetite, nanocomposite, XRD, SEM.
Graphical Abstract
[http://dx.doi.org/10.2217/17435889.2.6.861] [PMID: 18095851]
[http://dx.doi.org/10.1002/jbm.a.30836] [PMID: 17072849]
[http://dx.doi.org/10.1098/rsif.2017.0093] [PMID: 28404870]
[http://dx.doi.org/10.3390/ijms18040709] [PMID: 28350317]
[http://dx.doi.org/10.1016/S0168-3659(03)00066-X] [PMID: 12695060]
[http://dx.doi.org/10.1038/nnano.2007.387] [PMID: 18654426]
[http://dx.doi.org/10.1021/nl102184c] [PMID: 20726522]
[http://dx.doi.org/10.1039/C1CS15237H] [PMID: 22109657]
[http://dx.doi.org/10.1001/jama.1995.03520410048025] [PMID: 7715060]
[http://dx.doi.org/10.1212/WNL.43.3_Part_1.515] [PMID: 8450993]
[http://dx.doi.org/10.2105/AJPH.84.8.1261] [PMID: 8059882]
[http://dx.doi.org/10.1016/S1461-5347(98)00117-5] [PMID: 10234207]
[http://dx.doi.org/10.1016/S1359-6446(03)02623-0] [PMID: 12623240]
[http://dx.doi.org/10.1016/j.addr.2009.04.016] [PMID: 19422866]
[http://dx.doi.org/10.1517/17425240903427940] [PMID: 20095944]
[http://dx.doi.org/10.1021/cr900327d] [PMID: 20356105]
[http://dx.doi.org/10.1021/nl202559p] [PMID: 21846107]
[http://dx.doi.org/10.1002/adma.200400760]
[http://dx.doi.org/10.1016/j.jconrel.2006.04.007] [PMID: 16740332]
[http://dx.doi.org/10.1016/S1367-5931(02)00347-2] [PMID: 12133722]
[http://dx.doi.org/10.1016/j.biomaterials.2006.01.039] [PMID: 16504284]
[http://dx.doi.org/10.1038/nmat2608] [PMID: 20010827]
[http://dx.doi.org/10.1007/s10971-011-2595-4]
[http://dx.doi.org/10.1002/adma.201104763] [PMID: 22378538]
[http://dx.doi.org/10.1098/rsif.2017.0093]
[http://dx.doi.org/10.1016/j.jconrel.2006.05.006] [PMID: 16784793]
[http://dx.doi.org/10.1039/b701744h] [PMID: 17668088]
[http://dx.doi.org/10.1021/cm051198v]
[http://dx.doi.org/10.1016/j.jmmm.2005.01.035]
[http://dx.doi.org/10.1166/jnn.2014.9427] [PMID: 25942861]
[http://dx.doi.org/10.1134/S1087659610030090]
[http://dx.doi.org/10.1016/j.molcata.2013.05.007]
[http://dx.doi.org/10.1016/j.ijpharm.2009.03.013] [PMID: 19481693]
[http://dx.doi.org/10.1016/j.apsusc.2015.01.053]
[http://dx.doi.org/10.1016/j.carbpol.2010.10.032]
[http://dx.doi.org/10.1016/j.jmmm.2003.07.006]
[http://dx.doi.org/10.1016/j.molcata.2011.08.007]
[http://dx.doi.org/10.1021/cm702278u]
[http://dx.doi.org/10.1016/S0378-5173(02)00267-3] [PMID: 12176298]
[http://dx.doi.org/10.1016/j.mcat.2017.09.030]
[http://dx.doi.org/10.1002/ejic.201200469]
[http://dx.doi.org/10.1080/10611860290031868] [PMID: 12164381]
[PMID: 21445277]
[http://dx.doi.org/10.1016/j.ejpb.2010.07.007] [PMID: 20637869]
[http://dx.doi.org/10.1039/D1RA01027A]
[http://dx.doi.org/10.1039/C7DT03776G] [PMID: 29152624]
[http://dx.doi.org/10.1039/C7RA09243A]
[http://dx.doi.org/10.3390/nano8040248] [PMID: 29673172]